Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jonca Bull"'
Autor:
Saira Z. Sheikh, Tessa R. Englund, Susan W. Burriss, Jonca Bull, Anya Harry, James G. Groark, Ashley M. Hall, Michelle Miller, David A. Roth
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 9, Pp 747-752 (2022)
Clinical trials of novel therapeutics in the United States have not been adequately representative of diverse populations, particularly racial and ethnic minorities. The challenges and consequences of underrepresentation in clinical trial recruitment
Externí odkaz:
https://doaj.org/article/6488f9da571344e28af41ded75a82e23
Autor:
M. Larissa Avilés-Santa, John Heintzman, Nangel M. Lindberg, Rafael Guerrero-Preston, Kenneth Ramos, Ana L. Abraído-Lanza, Jonca Bull, Adolph Falcón, Mary Ann McBurnie, Ernest Moy, George Papanicolaou, Ileana L. Piña, Jennifer Popovic, Shakira F. Suglia, Miguel A. Vázquez
Publikováno v:
BMC Proceedings, Vol 11, Iss S11, Pp 1-12 (2017)
Abstract Persons of Hispanic/Latino descent may represent different ancestries, ethnic and cultural groups and countries of birth. In the U.S., the Hispanic/Latino population is projected to constitute 29% of the population by 2060. A personalized ap
Externí odkaz:
https://doaj.org/article/509b089c327f4d08a989705e0de6ad2f
Autor:
Lei Zhang, Howard L. McLeod, Jonca Bull, Todd C. Knepper, Martin Mendoza, Michael Pacanowski, Christine Merenda, Anuradha Ramamoorthy
Publikováno v:
Clinical Pharmacology and Therapeutics
Race, ethnicity, sex, and age are demographic factors that can influence drug exposure and/or response, and can consequently affect treatment outcome. We evaluated demographic subgroup enrollment patterns in new therapeutic products approved by the U
Autor:
David J. Cummings, Jonca Bull
Publikováno v:
Health Behavior and Policy Review. 2:485-492
Autor:
Grant D. Huang, Kelly Johnston McKee, Beth Harper, Elizabeth Mahon, Jonca Bull, Jamie Roberts
Publikováno v:
Contemporary clinical trials. 66
Patient recruitment is widely recognized as a key determinant of success for clinical trials. Yet a substantial number of trials fail to reach recruitment goals-a situation that has important scientific, financial, ethical, and policy implications. F
Autor:
Rafael Guerrero-Preston, M. Larissa Avilés-Santa, Ernest Moy, Ana L. Abraído-Lanza, Ileana L. Piña, Adolph Falcon, John Heintzman, Shakira F. Suglia, Miguel A. Vazquez, Kenneth S. Ramos, Nangel M. Lindberg, Jennifer R. Popovic, Mary Ann McBurnie, Jonca Bull, George J. Papanicolaou
Publikováno v:
BMC Proceedings, Vol 11, Iss S11, Pp 1-12 (2017)
BMC Proceedings
BMC Proceedings
Persons of Hispanic/Latino descent may represent different ancestries, ethnic and cultural groups and countries of birth. In the U.S., the Hispanic/Latino population is projected to constitute 29% of the population by 2060. A personalized approach fo
Autor:
Richard Pazdur, Yang-Min Ning, Anthony J. Murgo, Christine Merenda, Jonca Bull, Paul G. Kluetz, Michel D. Wissing
Publikováno v:
Cancer. 120:3025-3032
BACKGROUND US Food and Drug Administration (FDA) approval of new drugs depends on results from clinical trials that must be generalized to the US population. However, racial minorities are frequently under-represented in clinical studies. The enrollm
Autor:
Mark Chang, Katherine McCarthy, Charles Wakeford, Jonca Bull, Susan Kenley, Yuan-Yuan Chiu, Wenjin Wang
Publikováno v:
Journal of Biopharmaceutical Statistics. 17:775-789
This is the white paper on Innovative Approaches in Drug Development developed by the Biotechnology Industry Organization's (BIO) Clinical Trial Designs Workgroup. As recognized by the Food and Drug Administration's Critical Path Opportunities Report
Autor:
Richard Pazdur, Jonca Bull, Steven Lemery, Lola Fashoyin-Aje, Rajeshwari Sridhara, Patricia Keegan, Laura L. Fernandes
Publikováno v:
Journal of Clinical Oncology. 35:6518-6518
6518 Background: In New Drug- and Biologics License Applications, clinical trials provide the primary safety and efficacy data upon which approval decisions are made. Low numbers of patients from racial groups that experience higher incidence and/or
Autor:
Rajeshwari Sridhara, Laura L. Fernandes, Lola Fashoyin-Aje, Steven Lemery, Richard Pazdur, Patricia Keegan, Jonca Bull
Publikováno v:
Journal of Clinical Oncology. 35:6564-6564
6564 Background: In the US, statistics for Asians are often aggregated with other racial groups. This poses challenges in estimating the cancer burden and in defining cancer clinical trial enrollment targets in this demographic subgroup. ‘Asian‘